C18 C20
Conditions
Interventions
Group 1: Determination of septin9 methylation status is done in all patientens preoperative. Those with positive methylation-status are assigned to arm 1.
Group 2: Determination of septin9 methylation
Sponsors
Universitätsklinik für Allgemein- Viszeral und Thoraxchiirurgie, Proktologie der RUB
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: histological verified colon cancer within stage II-III histological verified rectal cancer within stage II-III signed declaration of consent
Exclusion criteria
Exclusion criteria: patients without complience or patinents who are not able to travel for repetitive examinations to hospital patients younger than 18 years pregnant or brestfeeding mothers secondary carcinomas patients with chronic gastritis, chronic esophagitis, non rheumatoid arthritis persons who are to be kept in an institution by judicial or official order
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome of the trial is overallsurvival. It will be determined separately for arm 1 with positive methylation-status at septin9 gene and arm 2 with negative methylation-status at septin9 gene. This survey will be done once a year routinely according to requirements of DKG-certified Darmzentrum. It will be done orally via a questionform and data will be stored at DKG-certified database kolorect. | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival within septin 9 positive patients overall survival within septin 9 negative patients disease free survival within septin 9 negative patients disease free survival within septin 9 positive patients | — |
Countries
Germany
Contacts
Public ContactErnst W. Kolbe
Universitätsklinik für Allgemein- Viszeral- und Thoraxchirurgie, Proktologie
Outcome results
None listed